G1 Therapeutics (GTHX) Receiving Somewhat Positive Press Coverage, Study Shows

News articles about G1 Therapeutics (NASDAQ:GTHX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. G1 Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0304203369385 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

G1 Therapeutics (NASDAQ:GTHX) traded down $0.04 during trading hours on Thursday, reaching $19.41. The company had a trading volume of 32,100 shares, compared to its average volume of 112,114. The company has a market cap of $550.47 and a P/E ratio of -9.03. G1 Therapeutics has a one year low of $12.04 and a one year high of $28.67.

A number of analysts have recently issued reports on GTHX shares. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. Finally, BTIG Research started coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $38.00 price target for the company. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.40.

In related news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark A. Velleca sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.01, for a total value of $150,075.00. The disclosure for this sale can be found here. Insiders sold a total of 541,406 shares of company stock valued at $10,746,719 in the last 90 days.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/28/g1-therapeutics-gthx-receiving-somewhat-positive-press-coverage-study-shows.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

What are top analysts saying about G1 Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for G1 Therapeutics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit